drugset / Trial / NCT07441486

A Single-arm, Prospective, Phase II Clinical Study of the Combination of Entinostat and Oral Paclitaxel in the Treatment of HR+HER2- Advanced Breast Cancer

NCT07441486

Phase 2 Not yet recruiting 50 enrolled Tianjin Medical University Cancer Institute and Hospital
NaSingle-groupOpen-labelTreatment

Summary

Objective: To explore the curative effect and safty of Changchun Ruibin metronomic chemotherapy combined with endistat in the treatment of HR positive HER2 negative advanced breast carcinoma.

Timeline

Start
2026-04-01
Primary completion
2026-04-10
Completion
2026-08-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Entinostat Small molecule
Subject Paclitaxel Small molecule Oral

Indications